Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population. Carel Jan Willem Borleffs

Transcription

1 Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population Carel Jan Willem Borleffs

2 The studies described in this thesis were performed at the Department of Cardiology of the Leiden University Medical Center, Leiden, the Netherlands. Cover: Daniël Samama Lay-out and print: Optima Grafische Communicatie, Rotterdam, the Netherlands ISBN: Copyright C. Jan Willem Borleffs, Leiden, the Netherlands. All right reserved, No part of this book may be reproduced or transmitted, in any form or by any means, without prior permission of the author. Financial support to the costs associated with publication of this thesis from Astellas Pharma, AstraZeneca BV, Biotronik Nederland BV, Boehringer Ingelheim BV, Boston Scientific BV, GE Healthcare, J.E. Jurriaanse Stichting, MEDA Pharma BV, Merck Sharp & Dohme BV, Novartis Pharma BV, Sanofi-Aventis BV, Schering-Plough BV, Servier Nederland BV, Siemens Nederland NV, St. Jude Medical Nederland BV, Toshiba Medical Systems Nederland, is greatly acknowledged.

3 Implantable Cardioverter Defibrillator Treatment: Benefits and Pitfalls in the Currently Indicated Population Proefschrift ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. P.F. van der Heijden, volgens besluit van het College voor Promoties te verdedigen op donderdag 30 september 2010 klokke uur door Carel Jan Willem Borleffs geboren te Pijnacker in 1981

4 Promotiecommissie Promotores: Prof. dr. M.J. Schalij Prof. dr. J.J. Bax Co-promotor: Dr. L. van Erven Overige leden: Dr. M. Bootsma Prof. dr. R.N.W. Hauer (UMC Utrecht) Dr. A. Mosterd (Meander Medisch Centrum Amersfoort) Prof. dr. F.R. Rosendaal Prof. dr. E.E. van der Wall

5 Ik ben misschien wat minder kind Dan destijds aan de start Maar alle dingen die ik doe Die doe ik met mijn hart. Toon Hermans Aan mijn ouders en aan Kim

6 Table of contents Chapter 1 Part I: General introduction and outline of the thesis Long-term follow-up and baseline risk stratification of ICD patients Chapter 2 Structured Care for Patients after Acute Myocardial Infarction: Sudden Cardiac Death Prevention. Data from the Leiden MISSION! AMI study. Europace 2010; 12: Chapter 3 Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Follow-up of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT). Eur Heart J 2009; 30: Chapter 4 Prognostic Importance of Atrial Fibrillation in Implantable Cardioverter Defibrillator Patients. J Am Coll Cardiol 2010; 55: Chapter 5 Clinical Importance of New-onset Atrial Fibrillation after Cardiac Resynchronization Therapy. Heart Rhythm 2009; 6: Chapter 6 Mortality Risk Score in Primary Prevention Implantable Cardioverter Defibrillator Recipients with Non-ischaemic or Ischaemic Heart Disease. Eur Heart J 2010; 31: Chapter 7 Prediction of Non-Benefit from Implantable Cardioverter Defibrillator Treatment in Primary Prevention Patients with Ischemic Heart Disease. Submitted Part II: New parameters in risk stratification Chapter 8 Infarct Tissue Heterogeneity Assessed with Contrast-Enhanced Magnetic Resonance Imaging Predicts Spontaneous Ventricular Arrhythmia in Patients with Ischemic Cardiomyopathy and Implantable Cardioverter-Defibrillator. Circ Cardiovasc Imaging 2009; 2: Chapter 9 Cardiac Sympathetic Denervation Assessed with 123-Iodine Metaiodobenzylguanidine Imaging Predicts Ventricular Arrhythmias in Implantable Cardioverter-Defibrillator Patients. J Am Coll Cardiol 2010;55:

7 Chapter 10 Predicting Ventricular Arrhythmias in Patients with Ischemic Heart Disease: Clinical Application of the ECG derived QRS-T Angle. Circ Arrhythm Electrophysiol 2009; 2: Chapter 11 Right Ventricular Stimulation Threshold at ICD implant Predicts Device Therapy in Primary Prevention Patients with Ischemic Heart Disease Europace 2010; in press Part III: Mechanical aspects and complications of device therapy Chapter 12 Inappropriate Implantable Cardioverter Defibrillator Shocks: Incidence, Predictors and Impact on Mortality. J Am Coll Cardiol 2010; in press Chapter 13 Requirement for Coronary Sinus Lead Interventions and Effectiveness of Endovascular Replacement during Long-term Follow-up after Implantation of a Resynchronization Device. Europace 2009; 11: Chapter 14 Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads. Circ Arrhythm Electrophysiol 2009; 2: Chapter 15 Implementation of Lead Safety Recommendations. Pacing Clin Electrophysiol 2010; 33: Chapter 16 Recurrent Implantable Cardioverter-Defibrillator Replacement Is Associated with an Increasing Risk of Pocket-Related Complications. Pacing Clin Electrophysiol 2010; in press Summary, Conslusions and Future Perspectives Samenvatting, Conclusies en Toekomstperspectief List of publications Dankwoord Curriculum Vitae

8